Long-term benzodiazepine use and salivary cortisol the netherlands study of depression and anxiety (NESDA)

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 160-168

  Manthey, Leonie ^a   Giltay, Erik J ^a   Van Veen, Tineke ^a   Neven, Arie Knuistingh ^a   Vreeburg, Sophie A ^b   Penninx, Brenda W J H ^a,b,c   Zitman, Frans G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anxiolytics; Benzodiazepines; Cortisol; Hpa axis; Long term use

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; DEXAMETHASONE; DIAZEPAM; HYDROCORTISONE; OXAZEPAM; TEMAZEPAM;

ADULT; ANXIETY DISORDER; ARTICLE; DEPRESSION; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALIVA LEVEL;

ADULT; ANXIETY DISORDERS; BENZODIAZEPINES; CIRCADIAN RHYTHM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; HYDROCORTISONE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; SALIVA; TIME FACTORS;

EID: 77952199171     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d41f41     Document Type: Article

References (41)

1. Abelson JL, Curtis GC, Cameron OG. Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res. 1996; 30: 79-93. (Pubitemid 26187527)
2. Curtis GC, Abelson. JL, Gold PW Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry. 1997 41: 76-85.
3. Fries E, Hellhammer DH, Hellhammer J. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. Psychoneuroendocrinology. 2006; 31: 1278-1288. (Pubitemid 44792374)
4. Lopez AL, Kathol RG, Noyes R. Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology. 1990; 15: 23-28. (Pubitemid 20099599)
5. Mcintyre IM, Norman TR, Burrows GD, et al. Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiol Int. 1993 10: 205-213.
6. Osman OT, Hsiao JK, Potter WZ. Dose dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. Psychopharmacology (Berl). 1993 111: 295-300.
7. Burrows GD, Norman TR, Judd FK, et al. Short-acting versus long-acting benzodiazepines-discontinuation effects in panic disorders. J Psychiatr Res. 1990 24: 65-72.
8. Christensen P, Gram. LF, Kraghsorensen P, et al. Afternoon cortisol levels before (spontaneous) and after suppression with dexamethasone or oxazepam in depressed-patients. J Affect Disord. 1986; 10: 171-176. (Pubitemid 16066696)
9. Pomara N, Willoughby LM, Sidtis JJ, et al. Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacology (Berl). 2005; 178: 1-8. (Pubitemid 40298685)
10. Risby ED, Hsiao JK, Golden RN, et al. Intravenous alprazolam challenge in normal subjects-biochemical, cardiovascular, and behavioral effects. Psychopharmacology (Berl). 1989; 99: 508-514. (Pubitemid 19273107)
11. Charney DS, Breier A, Jatlow PI, et al. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology (Berl). 1986; 88: 133-140. (Pubitemid 16148126)
12. Laakmann G, Wittmann M, Gugath M, et al. Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology (Berl). 1984; 84: 66-70. (Pubitemid 14032211)
13. Pomara N, Willoughby LM, Ritchie JC, et al. Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. Neuropsychopharmacology. 2004; 29: 605-611. (Pubitemid 38365938)
14. Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness-normalization of test result compared with clinical improvement. J Affect Disord. 1982; 4: 93-101. (Pubitemid 12076970)
15. Christensen P, Lolk A, Gram LF, et al. Benzodiazepine-induced sedation and cortisol suppression-a placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992 106: 511-516.
16. Gram LF, Christensen L, Kristensen CB, et al. Suppression of plasma-cortisol after oral administration of oxazepam, in man. Br J Clin Pharmacol. 1984; 17: 176-178. (Pubitemid 14097857)
17. Gram LF, Christensen P. Benzodiazepine suppression, of cortisol secretion-a measure of anxiolytic activity. Pharmacopsychiatry. 1986; 19: 19-22. (Pubitemid 16185724)
18. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines-side effects, abuse risk and alternatives. Am Fam Physician. 2000; 61: 2121-2128. (Pubitemid 30225617)
19. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal-prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988 45: 444-450.
20. Cowley DS, RoyByrne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder-effects of chronic alprazolam treatment. Neuropsychopharmacology. 1995 12: 147-157.
21. Penninx BWJH, Beekman ATF, Smit JH, et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. International Journal of Methods in Psychiatric Research. 2008 17: 121-140.
22. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD System [WHO Web site]. November 23, 2009. Available at: http://www.whocc.no/atcddd/. Accessed November 23, 2009.
23. Zitman FG, Couvee JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 2001 178: 317-324.
24. Zitman FG. Discontinueringsstrategieen. In: Kahn RS, Zitman. FG, eds. Farmacotherapie in de psychiatrie. Maarssen: Elsevier/Bunge; 1999: 165-177.
25. Oude Voshaar RC, Mol AJ, Gorgels WJ, et al. Cross-validation, predictive validity, and time course of the Benzodiazepine Dependence Self-Report Questionnaire in a benzodiazepine discontinuation trial. Compr Psychiatry. 2003 44: 247-255.
26. Kan CC, Breteler MHM, Timmermans EAY, et al. Scalability, reliability, and validity of the Benzodiazepine Dependence Self-Report Questionnaire in outpatient benzodiazepine users. Compr Psychiatry. 1999 40: 283-291.
27. Kan CC, Breteler MHM, van der Ven AHGS, et al. Cross-validation of the Benzodiazepine Dependence Self-Report Questionnaire in outpatient benzodiazepine users. Compr Psychiatry. 2001; 42: 433-439. (Pubitemid 32884852)
28. Vreeburg SA, Hoogendijk WJG, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity results from a large cohort study. Arch Gen Psychiatry. 2009 66: 617-626.
29. van Aken MO, Romijn JA, Miltenburg JA, et al. Automated measurement of salivary cortisol. Clin Chem. 2003 49: 1408-1409.
30. Pruessner JC, Kirschbaum C, Meinlschrnid G, et al. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology. 2003; 28: 916-931. (Pubitemid 36936799)
31. Bhattacharyya MR, Molloy GJ, Steptoe A. Depression is associated with flatter cortisol rhythms in patients with coronary artery disease. J Psychosam Res. 2008; 65: 107-113. (Pubitemid 352004040)
32. Vreeburg SA, Kruijtzer BP, van Pelt J, et al. Associations between sociodernographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. Psychoneuroendocrinology. 2009 34: 1109-1120.
33. Gueorguieva R, Krystal JH. Move over ANOVA-progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. Arch Gen Psychiatry. 2004; 61: 310-317. (Pubitemid 38295833)
34. Arvat E, Maccagno B, Ramunni J, et al. The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin Endocrinol Metab. 1999; 84: 2611-2615. (Pubitemid 30641981)
35. Breier A, Davis O, Buchanan R, et al. Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biol Psychiatry. 1992; 32: 880-890. (Pubitemid 23024900)
36. Desouza EB. Neuroendocrine effects of benzodiazepines. J Psychiatr Res. 1990 24: 111-119.
37. Schuckit MA, Hauger R, Klein. JL. Adrenocorticotropin hormone response to diazepam in healthy young men. Biol Psychiatry. 1992; 31: 661-669. (Pubitemid 20132238)
38. Voshaar RCO, Verkes RJ, van Luijtelaar GLJM, et al. Effects of additional oxazepam in long-term users of oxazepam. J Clin Psychopharmacol. 2005 25: 42-50.
39. Mikkelsen JD, Bundzikova J, Larsen MH, et al. GABA. regulates the rat hypothalamic-pitaitary-adrenocortical axis via different GABA-A receptor alpha subtypes. Ann N Y Acad Sci. 2008 1148: 384-392.
40. de Kloet ER, Vreugdenhil E, Oitzl MS, et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998; 19: 269-301. (Pubitemid 29117816)
41. Grottoli S, Giordano R, Maccagno B, et al. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab. 2002 87: 4616-4620.